Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H32N2O5 |
| Molecular Weight | 368.4678 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H](CCN1[C@@H](CCCCCCC(O)=O)C(=O)NC1=O)C2CCCCC2
InChI
InChIKey=ZIDQIOZJEJFMOH-JKSUJKDBSA-N
InChI=1S/C19H32N2O5/c22-16(14-8-4-3-5-9-14)12-13-21-15(18(25)20-19(21)26)10-6-1-2-7-11-17(23)24/h14-16,22H,1-13H2,(H,23,24)(H,20,25,26)/t15-,16+/m0/s1
| Molecular Formula | C19H32N2O5 |
| Molecular Weight | 368.4678 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6727564 |
https://www.ncbi.nlm.nih.gov/pubmed/1937072
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6727564 |
https://www.ncbi.nlm.nih.gov/pubmed/1937072
BW 245C is a DP receptor agonist. Systemic administration of BW 245C to healthy volunteers lead to inhibition of platelet aggregation responses to ADP. BW245C was found to be effective in reducing human intraocular pressure, but its clinical usefulness as anti-glaucoma drugs is limited by the extraocular side effects.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Behavioural, ECoG spectrum power and body temperature effects of BW 245C, a prostaglandin analogue after intraventricular microinjection in chicks. | 1981 May |
|
| Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors. | 1983 Jan |
|
| Effects of single oral dose administration of a hydantoin prostaglandin analogue BW 245C in man. | 1984 Jun 4 |
|
| Effects of prostaglandin D2 and its analogue, BW245C, on intraocular pressure in humans. | 1991 |
Patents
Sample Use Guides
In a pilot study in man BW 245C was administered orally in an aqueous solution, at doses 50 and 150 micrograms. Platelet aggregation responses to ADP were significantly inhibited only at 120 minutes after 150 micrograms of BW 245C. Topical application of BW245C reduces intraocular pressure in humans.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:31:56 GMT 2023
by
admin
on
Sat Dec 16 05:31:56 GMT 2023
|
| Record UNII |
5B26TJM1L8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5B26TJM1L8
Created by
admin on Sat Dec 16 05:31:56 GMT 2023 , Edited by admin on Sat Dec 16 05:31:56 GMT 2023
|
PRIMARY | |||
|
3080928
Created by
admin on Sat Dec 16 05:31:56 GMT 2023 , Edited by admin on Sat Dec 16 05:31:56 GMT 2023
|
PRIMARY | |||
|
72814-32-5
Created by
admin on Sat Dec 16 05:31:56 GMT 2023 , Edited by admin on Sat Dec 16 05:31:56 GMT 2023
|
PRIMARY |